Ticker brief
ZBIO
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
4
crowd 14d
·
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-13 · now +0.05 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 5 | +0.06 |
| @CrweWorld | C | · | 1 | +0.05 |
| @Brad_E_Schulz | C | · | 1 | +0.30 |
| @BiopharmIQ | B | · | 1 | +0.15 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 3 obexelimab results in IgG4-related disease. | · | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.10 | Zenas scheduled Phase 2 obexelimab lupus results for Q4 2026. | · | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.10 | Zenas plans to present Phase 2 relapsing-remitting multiple-sclerosis results on October 22, 2026. | · | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.10 | Zenas plans to present Phase 2 systemic-lupus results for Obexelimab in Q4 2026. | · | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.15 | Summarizes positive midday biotech stock moves alongside company catalysts. | · | tweet ↗ |
| 2026-10-07 | @Brad_E_Schulz | +0.30 | Quantifies intraday sector breadth and performance; ticker output is capped at six movers. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Announces upcoming presentations of multiple-sclerosis data and trial designs. | · | tweet ↗ |
| 2026-10-07 | @CrweWorld | +0.05 | Announces upcoming presentations of multiple-sclerosis data and trial designs. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.